Scarica l'app Stockscreener
1.452
1.75%
0.022
Dopo l'orario di chiusura:
1.45
-0.002
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.43
Aprire:
$1.45
Volume 24 ore:
578.23K
Relative Volume:
0.70
Capitalizzazione di mercato:
$72.13M
Reddito:
$300.00K
Utile/perdita netta:
$-27.61M
Rapporto P/E:
-2.5134
EPS:
-0.5777
Flusso di cassa netto:
$-22.17M
1 W Prestazione:
+3.93%
1M Prestazione:
+5.43%
6M Prestazione:
-36.46%
1 anno Prestazione:
+96.30%
Intervallo 1D:
$1.4226
$1.475
Intervallo di 1 settimana:
$1.34
$1.54
Portata 52W:
$0.67
$3.82
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.452 | 71.04M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-08 | Iniziato | Raymond James | Outperform |
| 2026-06-05 | Iniziato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Oppenheimer | Outperform |
| 2025-10-17 | Iniziato | Leerink Partners | Outperform |
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
Mostra tutto
iBio Inc Borsa (IBIO) Ultime notizie
iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan
Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan
Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan
Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - marketbeat.com
iBio Inc (IBIO) Stock News Today - TradingKey
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail
iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS
IBIO 8-K & SEC Filings - Yahoo Finance
iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et
iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan
iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India
iBio appoints Molly Carr as chief medical officer - Investing.com
Molly Carr named Chief Medical Officer at iBio - TradingView
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Balance Sheet - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
iBio Inc (IBIO) Cash Flow - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IBIO|iBio Inc|Price:1.385|Chg%:-0.065 - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IBIO Q2 2026 Earnings: Narrower Loss Beats Estimates; Pre-Revenue Status Remains ClearGuidance Accuracy Score - po-news-eg.net
iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView
TradingKey - TradingKey
Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat
IBIO|iBio Inc|Price:1.430|Chg%:+0.030 - TradingKey
iBio Inc (IBIO) Institutional Confidence - TradingKey
iBio Inc. (IBIO) Slips 1.09% as Biotech Sector Faces Headwinds – Key Support at $1.29 in FocusUndervalued Stocks - dars.gov.et
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail
iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
iBio Inc. Holds Steady at $1.51 as Biotech Stock Consolidates Near Key LevelsSupply Zone - dars.gov.et
We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm
iBio Inc. (IBIO) Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre‑Revenue PhaseBanking Earnings Report - DonanımHaber
iBio Inc. (IBIO) Retreats 1.85%, Approaching Key Support at $1.51Narrow Range Breakout - DonanımHaber
Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIOiBio Inc Latest SEC Filings - Finviz
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
iBio Inc Azioni (IBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Duran Felipe | Chief Financial Officer |
Mar 19 '26 |
Buy |
2.02 |
24,835 |
50,132 |
35,974 |
| Brenner Martin | See Remarks |
Mar 19 '26 |
Buy |
2.02 |
12,336 |
24,919 |
30,652 |
2.20%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):